Kobo Biotech News

Kobo Biotech AGM: Shareholders approve FY24 accounts

Kobo Biotech Limited shareholders unanimously approved the adoption of annual accounts for FY24 at its 31st AGM held on July 24, 2026. The resolution passed with 100% support via remote e-voting.

Kobo Biotech FY24 loss narrows to ₹49.29 lakh

Kobo Biotech Limited reported a net loss of ₹49.29 lakh for FY 2023-24, narrowing from ₹55.53 lakh in the previous year, with zero revenue from operations.

Kobo Biotech reports loss for FY 2023-24

Kobo Biotech reported a net loss of ₹49.28 lakh for FY 2023-24, with no revenue from operations. The company is currently under Corporate Insolvency Resolution Process.

Kobo Biotech NCLT Approves Beaufond Resolution Plan

NCLT Hyderabad approves Beaufond Industries' resolution plan for Kobo Biotech on May 11, 2026, with a total resolution amount of INR 70.11 crores and post-merger shareholding restructuring.

Kobo Biotech Files Q4 FY26 SEBI Compliance Certificate

Kobo Biotech Limited submitted its quarterly compliance certificate under SEBI Regulation 74(5) for Q4 FY26, confirming proper dematerialization processes through its registrar XL Softech Systems Ltd.